ArticleBMC cancer2025
F-18 FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAirway inflammation is believed to play a crucial role in the development and progression of non-small cell lung cancer (NSCLC). However, no study has yet employed quantified imaging biomarkers to assess airway inflammation in patients with NSCLC. This study aimed to validate the hypothesis that airway inflammation is more pronounced in a large cohort of patients with NSCLC compared to controls, using airway imaging biomarkers derived from fluorine-18-fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET), as well as to explore their associations with clinical parameters.
methodsWe retrospectively enrolled 618 patients with NSCLC and 441 controls who underwent F-18 FDG PET/computed tomography (CT). The F-18 FDG PET/CT images were subjected to airway segmentation to determine the airway maximum standardized uptake value (SUVmax) and total lesion glycolysis (TLG). We compared the airway PET parameters between patients with NSCLC and controls. Additionally, we investigated the associations between airway PET parameters and tumor SUVmax, stages, smoking pack-years, histological subtypes, systemic inflammation, and lung function in patients with NSCLC.
resultsThe median airway SUVmax (P < 0.0001) and TLG (P < 0.0001) were significantly higher in patients with NSCLC than in controls. The median airway SUVmax (P = 0.0098) and TLG (P < 0.0001) were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. Airway SUVmax and TLG showed weak positive correlations with tumor SUVmax, stages, white blood cell count, and neutrophil-to-lymphocyte ratio, but weak to moderate negative correlations with lung function parameters. Airway TLG showed a moderate positive correlation with smoking pack-years.
conclusionsF-18 FDG PET-derived airway imaging biomarkers were higher in patients with NSCLC than in controls. Additionally, these biomarkers were associated with tumor SUVmax, stages, histological subtypes, serologic inflammatory markers, lung function, and smoking, suggesting their potential to provide insights into the development and severity of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.